Enterin has an innovative discovery engine with several exciting molecules at different stages of development. Our molecules are synthetic derivatives of either shark or mammalian aminosterols. Our lead molecule, ENT-01, is being advanced through clinical development for the treatment of Parkinson’s Disease and other potential neurodegenerative diseases. Currently, we are investigating the benefit of ENT-01 in the treatment of various non-motor symptoms of Parkinson’s Disease, including psychosis (hallucinations), dementia, and potentially constipation, and also in the treatment of autism.
Learn more about our lead programs.